Lingsha Zhou

发表

Identification of comprehensive geriatric assessment‐based risk factors for insomnia in elderly Chinese hospitalized patients

Rong Liu, Wenchao Shao, Jonathan King-Lam Lai, 2021, Aging medicine (Milton (N.S.W)).

Prevalence and the factors associated with malnutrition risk in elderly Chinese inpatients

Rong Liu, Wenchao Shao, Jonathan King-Lam Lai, 2021, Aging medicine (Milton (N.S.W)).

Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.

H. Kantarjian, J. Cortes, S. Verstovsek, 2013, Leukemia research.

Significance of cytogenetic abnormalities in patients with polycythemia vera

H. Kantarjian, M. Sever, A. Quintás-Cardama, 2013, Leukemia & lymphoma.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelo ﬁ brosis

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021 .

Zhaofeng Chen, Q. Guo, Hongling Zhang, 2020, BioMed research international.

Improved survival of patients with myelofibrosis in the last decade: Single‐center experience

Z. Estrov, H. Kantarjian, S. Verstovsek, 2022, Cancer.

Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2021, Clinical lymphoma, myeloma & leukemia.

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

Z. Estrov, H. Kantarjian, S. Verstovsek, 2020, Cancer.

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions

S. Verstovsek, C. Bueso-Ramos, Julie Huynh-Lu, 2017, Annals of Hematology.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2013, Leukemia research.

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2011, Blood.

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.

M. Konopleva, Z. Estrov, S. Verstovsek, 2021, Blood advances.

In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer

Min Liu, Xiaomei Ma, Zhaofeng Chen, 2021, Translational cancer research.

Min Liu, Yongning Zhou, Ya Zheng, 2021 .

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Impact of SF3B1 mutation in myelofibrosis

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2022, Leukemia & lymphoma.

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

Comprehensive analysis to identify DNA damage response-related lncRNA pairs as a prognostic and therapeutic biomarker in gastric cancer.

Min Liu, Zhaofeng Chen, Q. Guo, 2021, Mathematical biosciences and engineering : MBE.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

H. Kantarjian, S. Verstovsek, E. Jabbour, 2019, Leukemia & lymphoma.

Min Liu, Zhaofeng Chen, Q. Guo, 2021, Frontiers in Molecular Biosciences.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

High Blast Percentage, Chromosome 17 Abnormalities and Severe Pancytopenia Predict Death within Twelve Months in Patients with Myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

H. Kantarjian, S. Verstovsek, E. Jabbour, 2016 .

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia

H. Kantarjian, J. Cortes, S. Verstovsek, 2012 .

Identification of the RP11-21C4.1/SVEP1 gene pair associated with FAT2 mutations as a potential biomarker in gastric cancer

Min Liu, Yongning Zhou, Ya Zheng, 2021, Bioengineered.

The role of therapy in the outcome of patients with myelofibrosis

Z. Estrov, H. Kantarjian, S. Verstovsek, 2023, Cancer.

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Verifying TCM Syndrome Hypothesis Based on Improved Latent Tree Model

Jun Zhang, Peng Chen, Bing Wang, 2018, ICIC.

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .